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Alterations in ER homeostasis have been implicated
in the pathophysiology of obesity and type-2diabetes
(T2D). Acute ER stress induction in the hypothalamus
produces glucose metabolism perturbations. How-
ever, the neurobiological basis linking hypothalamic
ERstresswith abnormal glucosemetabolism remains
unknown. Here, we report that genetic and induced
models of hypothalamic ER stress are associated
with alterations in systemic glucose homeostasis
due to increased gluconeogenesis (GNG) indepen-
dent of body weight changes. Defective alpha mela-
nocyte-stimulating hormone (a-MSH) production
underlies this metabolic phenotype, as pharmaco-
logical strategies aimed at rescuing hypothalamic
a-MSH content reversed this phenotype at metabolic
and molecular level. Collectively, our results posit
defective a-MSH processing as a fundamental medi-
ator of enhanced GNG in the context of hypothalamic
ER stress and establish a-MSHdeficiency in proopio-
melanocortin (POMC) neurons as a potential contrib-
utor to the pathophysiology of T2D.
INTRODUCTION
Perturbations in ER performance, and the subsequent develop-
ment of ER stress, have been implicated in the pathophysiology
of metabolic disorders such as obesity and type-2 diabetes
(T2D) (Ozcan et al., 2004, 2006). In particular, the hypothalamus
has emerged as a key area of theCNS, causally linking ER stress,
leptin resistance, and overweight (Cakir et al., 2013; Contreras
et al., 2014; Hosoi et al., 2008; Ozcan et al., 2009; Won et al.,
2009; Zhang et al., 2008). We have recently reported that thecellular responses to ER stress are modulated by Mitofusin 2
(Mfn2) (Mun˜oz et al., 2013; Schneeberger et al., 2013; Sebastia´n
et al., 2012), a GTPase-containing mitochondrial protein that
plays a prominent role in establishing mitochondria-ER con-
tacts (de Brito and Scorrano, 2008). Consistently, mice lacking
Mfn2 in hypothalamic proopiomelanocortin (POMC) neurons
(POMCMfn2KO), a subpopulation of anorexigenic neurons crit-
ical for energy and glucose homeostasis regulation (Grayson
et al., 2013; Schneeberger et al., 2014), exhibited an obesogenic
phenotype due to early ER-stress-induced leptin resistance
(Schneeberger et al., 2013).
Albeit the connection between hypothalamic ER stress and
obesity is well established, its potential contribution to the devel-
opment of glucose homeostasis alterations irrespective of body
weight has been scarcely investigated. Pharmacological and
genetic studies indicate that ER stress pathways in the hypo-
thalamus, and in POMC neurons, regulate whole-body glucose
metabolism (Purkayastha et al., 2011; Williams et al., 2014).
However, the precise molecular downstream mediators remain
undefined.
Here, we explored the mechanisms by which hypothalamic
POMCneurons, in the context of ERstress, contribute to systemic
glucosemetabolismdisturbances. To this aim,westudied genetic
and induced mouse models that develop early hypothalamic ER
stress. Our results establish alpha-melanocyte-stimulating hor-
mone (a-MSH), a neuropeptide derived from POMC processing,
as a key mediator of hypothalamic ER-stress-induced hepatic
gluconeogenesis (GNG) independent of obesity.
RESULTS
Deletion of Mfn2 in POMC Neurons Leads to Systemic
Alterations in Glucose Homeostasis Independently of
Obesity Development
Twelve-week-old POMCMfn2KO mice exhibit a dramatic obese
phenotype caused by hyperphagia and reduced thermogenesis.Cell Reports 12, 361–370, July 21, 2015 ª2015 The Authors 361
Figure 1. Defective Glucose Homeostasis in Weight-Matched POMCMfn2KO Mice Is Not Caused by Pancreatic Defects
(A–C) Fed and fasted glycemia (A), glucose tolerance (B), and insulin sensitivity (C) tests in control (n = 9–10) and POMCMfn2KO (n = 7–9) mice.
(D and E) Plasma insulin (D) and in vivo GSIS (E) in control (n = 10) and POMCMfn2KO (n = 7) mice.
(F and G) Pancreatic beta/alpha cell mass (F) and representative fluorescence images (G) of pancreatic islets (n = 3/genotype).
(H) Tissue-specific glucose uptake in soleus muscle (Sol), gastrocnemius muscle (Gas), liver (Liv), and epididymal white adipose tissue (eWAT) in control (n = 3)
and POMCMfn2KO (n = 4) mice.
Data are expressed as mean ± SEM. **p < 0.01. NS, not significant. The scale bar represents 50 mm. See also Figure S1.As expected, these mice showed marked alterations in glucose
homeostasis including hyperglycemia, hyperinsulinemia, glucose
intolerance, and insulin resistance (Schneeberger et al., 2013; Fig-
ures S1A–S1D).
To discriminate whether abnormal glucose homeostasis was a
primary defect or secondary to obesity, we performed subse-
quent studies in 6-week-old POMCMfn2KOmice when no differ-
ences in body weight or adiposity were recorded (Schneeberger
et al., 2013). Weight-matched POMCMfn2KO mice exhibited
fasting hyperglycemia (Figure 1A), glucose intolerance (Fig-
ure 1B), and insulin resistance (Figure 1C). Together, these re-
sults demonstrate defective glucose control in POMCMfn2KO
mice irrespective of body weight.362 Cell Reports 12, 361–370, July 21, 2015 ª2015 The AuthorsIncreased Hepatic Glucose Production in Young
Weight-Matched POMCMfn2KO Mice
Pancreatic b-cell dysfunction may cause abnormal glucose ho-
meostasis. However, no alterations in plasma insulin (Figure 1D),
glucose-stimulated insulin secretion (GSIS) (Figure 1E), pancre-
atic islet architecture, and number (control: 46 ± 9 islets/cm2
versus POMCMfn2KO: 60 ± 6 islets/cm2; NS; n = 3/genotype)
or pancreatic a/b-cell mass (Figures 1F and 1G) were observed
in 6-week-old weight-matched POMCMfn2KO mice, indicating
normal pancreatic islet mass and function.
To assess the contribution of individual insulin-sensitive tis-
sues to the development of glucose metabolism perturbations
in POMCMfn2KO mice, we measured in vivo glucose uptake
Figure 2. Enhanced Hepatic GNG in Weight-Matched POMCMfn2KO Mice
(A–D) Pyruvate tolerance test (A) and area under the curve (AUC) (B) and glycerol tolerance test (C) and AUC (D) of control (n = 9–11) and POMCMfn2KO
(n = 5–7) mice.
(E) Heatmap representation of relative gene expression changes in livers from control (n = 3) and POMCMfn2KO (n = 4) mice.
(F) PEPCK activity in liver homogenates from control (n = 9) and POMCMfn2KO (n = 15) mice.
(G) Plasma triglyceride concentration in control (n = 6) and POMCMfn2KO (n = 8) mice.
(H and I) Liver weight (H) and triglyceride content (I) in control (n = 6) and POMCMfn2KO (n = 7) mice.
(J) Expression of key lipid metabolism genes in livers from control and POMCMfn2KO mice (n = 6/genotype). Hprt was used as housekeeping gene.
Data are expressed as mean ± SEM. BW, body weight. *p < 0.05. See also Figure S2 and Tables S1 and S2.following a glucose load. 2-[3H]deoxyglucose (2DG) uptake in
POMCMfn2KO mice was similar to control counterparts in
all tested tissues, although a non-significant trend to exhibit
higher values in skeletal muscle was observed in mutant mice
(Figure 1H). Nevertheless, this observation could not explain
the impaired glucose homeostasis observed in POMCMfn2KO
mice and it could represent a secondary compensatory
mechanism.The liver is a major regulator of whole-body glucose homeo-
stasis through hepatic glucose production (HGP). Pyruvate
tolerance test (PTT) and glycerol tolerance tests (GlyTTs)
were used to assess HGP due to the difficulty to perform
hyperinsulinemic-euglycemic clamps at such a young age
(4 weeks). POMCMfn2KO mice displayed significantly higher
blood glucose levels (Figures 2A–2D), suggestive of enhanced
HGP.Cell Reports 12, 361–370, July 21, 2015 ª2015 The Authors 363
Figure 3. Reduced a-MSH Underlies Hypothalamic ER-Stress-Induced Hepatic GNG in POMCMfn2KO Mice
(A) Immunofluorescence images showing a-MSH staining in the PVN from 6-week-old control and POMCMfn2KO mice and integrated density quantification
(n = 3/genotype). 3V, third ventricle.
(legend continued on next page)
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In an attempt to determine the hepatic molecular alterations
leading to enhancedGNG, we performed a global transcriptomic
analysis in livers fromyoungweight-matchedPOMCMfn2KOand
control mice (Table S1). To establish relevant dysregulated path-
ways, we conducted associated disease analyses. The most
highly enriched category was ‘‘nutritional and metabolic dis-
eases,’’ with 535 transcripts significantly altered (Figure S2A;
Table S2). A large proportion of these transcripts (62%) belonged
to thesubcategory ‘‘glucosemetabolismdisorders’’ (FigureS2B).
Consistent with enhanced HGP, the expression of key hepatic
gluconeogenic genes such as cAMP responsive element-binding
protein 1 (Creb1), glucose 6-phosphatase (G6pc), and cytosolic
phosphoenolpyruvate carboxykinase (Pck1) was increased in
mutant mice (Figure 2E; Table S2). Overexpression of these
genes was validated by qRT-PCR (Figure S2C). Hepatic phos-
phoenolpyruvate carboxykinase (PEPCK) enzyme activity was
also increased in POMCMfn2KO mice (Figure 2F). No changes
in liver glycogen content were observed (control: 2.85 ±
0.97 mg/mg liver versus POMCMfn2KO: 3.34 ± 0.76 mg/mg liver;
NS; n = 15/genotype). These results suggest that enhancedGNG
is a major contributor to altered glucose homeostasis in weight-
matched POMCMfn2KOmice.
In contrast, hepatic lipidmetabolismwasunperturbed inmutant
mice, as no changes in plasma triglycerides (Figure 2G), liver
weight (Figure 2H), hepatic triglyceride concentration (Figure 2I),
and expression of key enzymes such as acetyl-CoA carboxylase
(Acaca), fatty acid synthase (Fasn), diacylglycerol acyltransferase
2 (Dgat2), stearoyl-coenzyme A desaturase 1 (Scd1), or carnitine
palmitoyltransferase 1 (Cpt1a) were observed (Figure 2J).
Next, we assessed biological parameters of hypothalamic-pi-
tuitary-adrenal axis function. Plasma concentration of epineph-
rine (control: 23.6 ± 1.2 pg/ml versus POMCMfn2KO: 27.1 ±
2.7 pg/ml; NS; n = 5–7/genotype), norepinephrine (control:
235 ± 50 pg/ml versus POMCMfn2KO: 280 ± 47 pg/ml;
NS; n = 5–7/genotype), adenocorticotropic hormone (control:
48.8 ± 7.1 pg/ml versus POMCMfn2KO: 76.3 ± 19.3 pg/ml; NS;
n = 5–7/genotype), and corticosterone (basal control: 48.2 ±
12.3 pg/ml versus basal POMCMfn2KO: 68.3 ± 21.2 pg/ml;
NS; n = 6–9/genotype; stressed control: 447 ± 25 pg/ml versus
stressed POMCMfn2KO: 451 ± 35 pg/ml; NS; n = 6–9/genotype)
was unaltered. Together, these results suggest that neither
defective insulin counter-regulatory hormones nor hypothalam-
ic-pituitary-adrenal axis function mediates the enhanced GNG
observed in POMCMfn2KO mice.
Reduced a-MSH in POMCMfn2KO Mice Underlies
Enhanced GNG
Hypothalamic POMC neurons release a-MSH, a critical neuro-
peptide implicated in energy balance and metabolic control(B–E) Vehicle (V) or a-MSHwere administered i.c.v. and PTT (B), its AUC (C), expre
(n = 6/group).
(F) Liver immunoblots for CREB and pCREB expression after acute i.c.v. adminis
(G) Densitometric quantification.
(H) Hypothalamic levels of a-MSH after acute central administration of V or TUD
(I and J) PTT (I) and AUC (J) after central administration of V or TUDCA in contro
(K) Expression of hepatic gluconeogenic genes after central administration of V
Data are expressed as mean ± SEM. *p < 0.05; **p < 0.01. The scale bar represe(Schneeberger et al., 2014). Weight-matched 6-week-old
POMCMfn2KO mice displayed decreased hypothalamic a-MSH
content (Schneeberger et al., 2013) and staining in neuronal
projections to target areas such as the paraventricular nucleus
(PVN) (Figure 3A). To investigate whether augmented GNG re-
sulted from reduced a-MSH production, we assessed the effects
of intracerebroventricular (i.c.v.) administration of this peptide.
Acute i.c.v. a-MSH delivery to POMCMfn2KO mice normalized
GNG(Figures3Band3C).Consistently, expressionof hepaticglu-
coneogenic enzymes Pck1 and G6pc (Figure 3D), as well as
PEPCK activity (Figure 3E), was restored after central a-MSH
administration.
The Effects of a-MSH on HGP in POMCMfn2KOMice Are
Mediated by CREB
Transcriptome analysis identified Creb1 as a differentially ex-
pressed gene in livers from POMCMfn2KO mice (Figures 2E
and S2C). Key gluconeogenic genes, including Pck1 and
G6pc, contain cAMP responsive elements (CRE) (Altarejos and
Montminy, 2011), and thus, we assessed whether Creb1 medi-
ated the effects of hypothalamic a-MSH on GNG. Consistent
with transcriptomic data, liver homogenates from weight-
matched 6-week-old POMCMfn2KO mice showed increased
CREB protein content, which was unchanged after i.c.v.
a-MSH administration (Figures 3F and 3G). CREB activity is
mainly regulated by phosphorylation (Altarejos and Montminy,
2011). Liver phospho-CREB (pCREB) levels in POMCMfn2KO
were also elevated (Figures 3F and 3G). Remarkably, acute
i.c.v. a-MSH was able to normalize pCREB levels to control
values (Figures 3F and 3G). To assess the relevance of these
findings, we investigated the effects of the manipulation of
CREB phosphorylation status using the PKA selective inhibitor
Rp-cAMPS, which effectively inhibits GNG (Dragland-Meserve
et al., 1986). POMCMfn2KO mice treated with Rp-cAMPS dis-
played a normalized PTT, consistent with reduced gluconeo-
genic capacity (Figure S3). Together, these results indicate that
a-MSH deficiency in POMCMfn2KO mice leads to enhanced
gluconeogenic programming mediated by CREB.
ER-Stress-Associated Reduction of a-MSH Is the Cause
of Enhanced HGP in POMCMfn2KO Mice
Decreased a-MSH content, in the context of hypothalamic ER
stress, is normalized after ER stress relief by central chaperone
treatment (Cakir et al., 2013; Schneeberger et al., 2013). Thus,
we evaluated the acute effects of i.c.v. delivery of the chemical
chaperone tauroursodeoxycholic acid (TUDCA) on GNG in
POMCMfn2KOmice. This treatment was able to normalize hypo-
thalamic a-MSH content (Figure 3H) and ameliorated the gluco-
neogenic response to pyruvate in POMCMfn2KO mice (Figuresssion of hepatic gluconeogenic genes (D), and PEPCK activity (E) were assayed
tration of V or a-MSH (n = 4/group). All samples were run on the same gel.
CA in control (n = 3–4/group) and POMCMfn2KO (n = 5/group) mice.
l (n = 7/group) and POMCMfn2KO (n = 10/group) mice.
or TUDCA in control (n = 3–4/group) and POMCMfn2KO (n = 5/group) mice.
nts 100 mm. See also Figure S3.
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3I and 3J). Hepatic expression of gluconeogenic genes was also
recovered after TUDCA administration (Figure 3K). Collectively,
our data suggest that augmented GNG in POMCMfn2KO mice
is the consequence of ER-stress-driven reduction of hypotha-
lamic a-MSH levels.
Short-Term HFD Administration Causes ER-Stress-
Mediated Reduction of Hypothalamic a-MSH Content
and Enhanced HGP in the Absence of Obesity
The relevance of hypothalamic a-MSH in the regulation of GNG
was further investigated in a pathophysiological model that reca-
pitulates the effects ofWestern diets upon glucose homeostasis.
To this end, we fedC57Bl/6Jmicewith high-fat diet for 4 consec-
utive days (4d-HFD), a sufficiently brief time interval to avoid
weight gain as a possible confounding factor. Consistent with
previous reports (Lee et al., 2011; Wang et al., 2001; Wiedemann
et al., 2013), short-term HFD feeding caused no significant
changes in body weight (Figure 4A) or plasma leptin levels
(Figure 4B) but induced fasting hyperglycemia (Figure 4C),
hyperinsulinemia (Figure 4D), and impaired pyruvate tolerance
(Figure 4E) when compared to counterparts fed with normal
chow diet (NCD). Consistently, increased expression of liver glu-
coneogenic genes (Figure 4F) and PEPCK activity (Figure 4G)
were observed in 4d-HFD mice.
Themolecular mechanisms underlying these rapid detrimental
effects on glucose homeostasis after short-term HFD feeding
are incompletely understood. We explored whether 4d-HFD
regime was sufficient to enable ER stress in the hypothalamus
of C57Bl/6J mice. We found that 4d-HFD feeding significantly
increased the transcript expression of key ER stress markers,
such as activating transcription factor 4 (Atf4) and 6 (Atf6),
spliced form of X-box-binding protein 1 (Xbp1s), and binding
immunoglobulin protein (BiP/Hspa5), suggesting enhanced hy-
pothalamic ER stress (Figure 4H). Protein expression analysis
of ER stress mediators in the hypothalamus from 4d-HFD mice
also showed a significant increase of PERK phosphorylation
(Figure 4I), which is a major transducer of the ER stress response
in the hypothalamus (Ozcan et al., 2009), and a trend to increase
in other ER stress markers (Figure S4A). Mfn2 expression was
reduced in the hypothalamus of 4d-HFD (Figure 4J). Remark-
ably, the deleterious effects of short-term HFD were associated
with reduced hypothalamic a-MSH content (Figure 4K) and
fiber staining in neuronal projections to the PVN (Figure 4L)
despite unaltered Pomc mRNA (NCD: 100% ± 13% versus
4d-HFD: 97% ± 12%; NS; n = 7/group), POMC protein content
(Figure 4M), or POMC neuron number (NCD: 983 ± 40 versus
4d-HFD: 993 ± 76; NS; n = 3/group). The reduced a-MSH/Figure 4. Short-Term HFD Causes Enhanced GNG in the Absence of O
(A–G) Effects of NCD or 4d-HFD in C57BL/6J mice on (A) body weight (n = 10/g
(D) plasma insulin (n = 8/group), (E) PTT (n = 10/group), (F) hepatic expression of
(H) Hypothalamic mRNA expression of ER stress markers (n = 12/group).
(I and J) Hypothalamic PERK phosphorylation (n = 6/group; I) and Mfn2 protein l
(K and L) Hypothalamic a-MSH content (n = 6/group; K) and immunofluorescenc
integrated density quantification (n = 3/genotype; L).
(M) Hypothalamic POMC content (n = 6/group).
(N) PTT and AUC after central administration of vehicle or a-MSH (n = 6 to 7/gen
Data are expressed as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. The scaPOMC ratio suggests defective POMC processing. However,
no changes in the transcript expression of the main POMC con-
vertases were observed in the hypothalamus of 4d-HFD mice
(Figure S4B). Given that proconvertase (PC) 1/3 and PC2 are
regulated at protein level rather than mRNA level (Cakir et al.,
2013), we conducted immunoblot analysis. Whereas PC1/3
expression was unchanged, PC2 levels were increased in the hy-
pothalami from 4d-HFDmice (Figure S4C), likely as a compensa-
tory mechanism to maintain adequate melanocortin tone.
To demonstrate a causal relationship between defective hypo-
thalamic a-MSH levels and increased GNG, we conducted i.c.v.
a-MSH administration studies. Acute delivery of a-MSH was
able to restore pyruvate tolerance in 4d-HFD mice (Figure 4N).
DISCUSSION
Enhanced hepatic GNG is a major contributor of fasting hyper-
glycemia in T2D patients (DeFronzo et al., 1989; Magnusson
et al., 1992). In addition to the classical hormonal regulatory
mechanisms, the brain has long been recognized as a key regu-
lator of this biological process (Bisschop et al., 2015) and hypo-
thalamic POMC neurons have recently emerged as a relevant
neuronal population implicated in the regulation of HGP (Ber-
glund et al., 2012, 2013; Claret et al., 2011; Shi et al., 2013; Wil-
liams et al., 2014; Xu et al., 2010). Given that acute ER stress
induction in the hypothalamus produces glucose metabolism al-
terations in a body-weight-independent manner (Purkayastha
et al., 2011), we investigated the molecular link between ER
stress in POMC neurons and glucose homeostasis.
Wehave recently reported thatMfn2criticallymodulatescellular
ER stress responses (Mun˜oz et al., 2013). Consistently, deletion of
Mfn2 leads to ER stress in vitro and in vivo (Ngoh et al., 2012;
Schneeberger et al., 2013; Sebastia´n et al., 2012). In POMC neu-
rons, Mfn2 deficiency causes an obesogenic phenotype charac-
terized by early hypothalamicER-stress-induced leptin resistance
(Schneeberger et al., 2013). Remarkably, POMCMfn2KO mice
exhibit abnormal glucose homeostasis before the onset of obesity
due to enhanced GNG. Along the same lines, our short-term HFD
model recapitulated the phenotypical outcome of POMCMfn2KO
mice, defined by reduced hypothalamic Mfn2 expression, ER
stress, and enhanced gluconeogenic capacity in the absence of
changes in body weight.
Defective processing and production of a-MSH neuropeptide
has been proposed to constitute the underlying neurobiological
basis of hypothalamic ER stress in obesity (Cakir et al., 2013;
Schneeberger et al., 2013). Similarly, 4 days of HFD administra-
tion also caused a reduction in hypothalamic a-MSH content andbesity due to ER-Stress-Associated Reduction in a-MSH
roup), (B) plasma leptin (n = 8/group), (C) fasting blood glucose (n = 8/group),
gluconeogenic genes, and (G) PEPCK activity (n = 8/group).
evels (n = 6/group; J).
e images showing a-MSH staining in the PVN from NCD or 4d-HFD mice and
otype/treatment).
le bar represents 100 mm.
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fiber staining in the PVN. Even though abnormal a-MSH traf-
ficking to target areas cannot be completely ruled out, the
reduced a-MSH/POMC ratio suggests that defective POMCpro-
cessing is the likeliest cause in both models studied. Our data
also indicate that processing perturbations are the consequence
of intrinsic factors (e.g., POMC protein misfolding) rather than
defective PC expression.
In view of these results, it was reasonable to speculate that
altered a-MSH content was also implicated in the development
of inadequate glucose homeostasis in the context of hypo-
thalamic ER stress. Indeed, our data demonstrate a causative
involvement of a-MSH in the maintenance of systemic glucose
homeostasis, as restoration of hypothalamic a-MSH levels,
either by direct administration of this peptide and/or pharmaco-
logical ER stress relief, normalized HGP in these mouse models.
The beneficial effects of the pharmacological treatment are likely
mediated through direct actions on POMC neurons, although we
cannot exclude potential effects on other hypothalamic areas
due to the delivery route used.
The precise mechanisms by which hypothalamic a-MSH con-
trols hepatic GNG are still incompletely understood, although a
key mediator appears to be the modulation of CREB activity in
the liver. CREB is considered a master positive regulator of glu-
coneogenic gene expression (Altarejos and Montminy, 2011;
Erion et al., 2009; Herzig et al., 2001, 2003). However, conditional
genetic ablation of Creb1 in adult hepatocytes did not cause al-
terations in glucose metabolism or expression of gluconeogenic
genes (Lee et al., 2014). This suggests functional redundancy,
and thus we cannot exclude modulatory effects of a-MSH on
other proteins that bind to CREs.
Extensive evidence indicates that the hypothalamus, and
particularly the melanocortin system, regulates HGP through
multisynaptic connections to autonomic centers (Bisschop
et al., 2015). Recent studies have used genetic deletion and re-
expression strategies to delineate the role of melanocortin
signaling in sympathetic and parasympathetic preganglionic
neurons (Berglund et al., 2014; Rossi et al., 2011). Reactivation
of melanocortin 4 receptors (MCR4s), which bind a-MSH, in all
cholinergic neurons attenuated hyperglycemia and hyperinsuli-
nemia, whereas its selective re-expression in brainstem neurons
was sufficient to improve hyperinsulinemia (Rossi et al., 2011).
This suggests that MC4R signaling in cholinergic preganglionic
sympathetic neuronsmediates HGP suppression. This is consis-
tent with our data demonstrating that reducedmelanocortin tone
in POMCMfn2KO or short-term HFD-fed mice is associated with
increased GNG. The importance of the sympathetic outflow on
the hypothalamic regulation of HGP is further supported by other
studies (Purkayastha et al., 2011; van den Hoek et al., 2008). In
this sense, preliminary results showed that prazosin (an alpha-1
adrenergic receptor blocker) was able to reverse enhanced HGP
in POMCMfn2KO mice (M.S., A.G.G.-V., and M.C., unpublished
data). Thus, it is tempting to speculate that a-MSH actions are
mediated by sympathetic innervation, although the precise
mechanisms by which POMC neurons propagate this signal
remain unknown.
In summary, here we demonstrate that pathophysiological sit-
uations associated with hypothalamic ER stress cause systemic
glucose homeostasis perturbations, named enhanced GNG, in368 Cell Reports 12, 361–370, July 21, 2015 ª2015 The Authorsthe absence of obesity. We provide evidence that deficient
a-MSH output, which is exclusively released by POMC neurons,
is a critical mediator of hypothalamic ER-stress-induced GNG.
These results provide further understanding of the central
mechanisms involved in HGP regulation and establish a-MSH
processing defects in POMC neurons as a potential contributor
to the pathophysiology of T2D.
EXPERIMENTAL PROCEDURES
Mice and Diets
C57BL/6J mice were purchased from Harlan Europe. The generation of
POMCMfn2KO mice has been previously reported (Schneeberger et al.,
2013). Mice were maintained on a 12:12 hr light-dark cycle with free access
to water and NCD (Harlan Research Laboratories) or HFD (45% kcal fat;
Research Diets) for 4 days (starting at 6 weeks of age). POMCMfn2KO male
mice were studied at 5 to 6 weeks of age or otherwise stated. In vivo studies
were performed with approval of the University of Barcelona Ethics Commit-
tee, complying with current Spanish and European legislation.
Physiological Measurements
Blood samples were collected via tail vein or trunk bleeds using a capillary
collection system (Sarstedt). Blood glucose was measured using a Glucome-
ter (Arkray). GTT (D-glucose; 2 g/kg), GSIS (D-glucose; 3 g/kg), PTT (sodium
pyruvate; 1 g/kg), and GlyTT (glycerol; 1 g/kg) were performed on overnight
fasted mice. Insulin sensitivity tests (0.4 IU/kg) were performed on 6 hr food-
deprived mice. All compounds were i.p. injected and blood glucose deter-
mined at the indicated time points. Plasma hormones were measured by
commercially available ELISA kits in overnight fasted mice: insulin (Crystal-
chem); leptin (Crystalchem); epinephrine and norepinephrine (Labor Diagnos-
tika Nord); adrenocorticotropic hormone (Abnova); and corticosterone
(Immuno Diagnostic Systems). Plasma triglycerides were measured using
quantitative enzymatic determination TAG kit (Sigma-Aldrich).
Hypothalamic POMC, a-MSH Content, and Immunohistochemistry
Mice were transcardially perfused with 4%paraformaldehyde, overnight fixed,
cryoprotected in 30% sucrose, and frozen. Brains were cut into 25-mm-thick
slices using a sliding microtome. Hypothalamic slices were extensively
washed in KPBS buffer and blocked in 2% donkey serum in KPBS plus
0.4% Triton X-100. Sections were incubated with a-MSH antibody
(1:20,000; Chemicon) or POMC antibody (1:1,000; Phoenix Pharmaceuticals)
in blocking buffer for 48 hr at 4C. After washing with KPBS, slices were incu-
bated with the appropriate Alexa 488 antibody (1:400; Molecular Probes).
Imaging was performed using a Leica DMI 6000B microscope. a-MSH inte-
grated density after image skeletonization was calculated using ImageJ soft-
ware. POMC neurons were counted in equivalent ARC sections (bregma
1.46 to 1.94). For a-MSH content, hypothalami were sonicated in 500 ml
of 0.1 N HCl solution. Lysates were centrifuged and supernatants used for
the quantification of a-MSH by ELISA (Phoenix Pharmaceuticals). Protein con-
centration was determined by Bradford.
qRT-PCR
Hypothalami and livers were harvested and immediately frozen in liquid
nitrogen. mRNA was isolated using Trizol. Retrotranscription and qRT-PCR
was performed as previously described (Claret et al., 2011). Transcript
levels were measured using the ABI Prism 7900 HT system (Applied
Biosystems). Proprietary Taqman Gene Expression assay FAM/TAMRA
primers used (Applied Biosystems) were Acaca (Mm01304277_m1),
Atf4 (Mm00515324_m1), Atf6 (Mm01295317_m1), Cpe (Mm00516341_m1),
Cpt1a (Mm00550438_m1), Creb1 (Mm00501607_m1), Ddit3 (Mm00492097_
m1), Dgat2 (Mm00499536_m1), Fasn (Mm00662319_m1), G6pc
(Mm00839363_m1), Hprt (Mm00446968_m1), Hspa5 (Mm00517691_m1),
Pck1 (Mm00440636_m1), Pcsk1 (Mm00479023_m1), Pcsk2 (Mm00500981_
m1), Prcp (Mm00804502_m1), Scd1 (Mm01197142_m1), and Xbp1s
(Mm03464496_m1).
Western Blot Analysis
Protein lysates were prepared from pulverized whole-liver samples or medio-
basal hypothalamic microdissections in RIPA buffer (Sigma-Aldrich) supple-
mented with protease and phosphatase inhibitors. Cleared supernatants
were resolved on pre-cast gradient 4%–12% SDS-PAGE gels (Bio-Rad),
transferred onto PVDF membranes (Millipore), and probed with the following
primary antibodies: phospho CREB (Ser133; 1:1,000; Cell Signaling Technol-
ogy); CREB (1:1,000; Cell Signal); Mfn2 (1:1,000; Abcam); phospho PERK
(1:1,000; Cell Signaling); PERK (1:1,000; Cell Signal); XBP1 (1:1,000; Abcam);
p-eiF2a (1:1,000; Cell Signal); ATF4 (1:1,000; Aviva Systems Biology), ATF6
(1:1,000; Santa Cruz Biotechnology); CHOP (1:1,000; Santa Cruz); PC1
(1:5,000; MyBiosource); PC2 (1:5,000; MyBiosource), alpha-tubulin (1:8,000;
Sigma-Aldrich); and beta-actin (1:5,000; Sigma-Aldrich). Detection was per-
formed by enhanced chemiluminescence (Pierce). Band intensities were
quantified using the ImageJ software.
i.c.v. Cannulation and Treatments
i.c.v. surgery was performed at 9 weeks of age as previously described
(Schneeberger et al., 2013). On experimental days, 10-week-old control and
POMCMfn2KO mice or C57BL/6J mice fed with NCD or HFD for 4 days
were fasted overnight and infused with 2 ml of either vehicle (aCSF; Tocris
Bioscience), a-MSH (1 nmol/ml; Sigma-Aldrich), or TUDCA (2.5 mg/ml; Calbio-
chem) just after lights on. Two hours later, a PTT was performed. For TUDCA
experiments, an extra i.c.v. injection was performed just before fasting.
Statistics
Data are expressed as mean ± SEM. p values were calculated using unpaired
Student’s t test, two-way ANOVA, or one-way ANOVA with post hoc Sidak
multiple comparisons test as appropriate. p < 0.05 was considered significant.
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